PMN Company Profile and Key Details

Q: Who are the executives of PMN?

Dr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Senior ConsultantMr. Dennis Chen Ph.D.Head of Manufacturing & Senior ConsultantDr. Larry Douglas Altstiel M.D., Ph.D.Chief Medical OfficerMr. Gavin T. MalenfantChief Operating OfficerDr. Gail M. Farfel Ph.D.Chief Executive Officer & DirectorDr. David Wishart Ph.D.Chief Physics OfficerDr. Neil R. Cashman M.D.Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & DirectorDr. Johanne Kaplan Ph.D.Chief Devel. OfficerMr. Eugene WilliamsCo-Founder & Chairman

NASDAQ : PMN

ProMIS Neurosciences

$13.78

0.23+1.70%

At Close 4:00 PM

66.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ProMIS Neurosciences, Inc. (PMN) stock surged +1.70%, trading at $13.78 on NASDAQ, up from the previous close of $13.55. The stock opened at $13.82, fluctuating between $13.41 and $13.96 in the recent session.

Stock Snapshot

13.55

Prev. Close

18.02M

Market Cap

13.41

Day Low

-1.18

P/E Ratio

-11.66

EPS (TTM)

-0.57

Cash Flow per Share

13.82

Open

1.31M

Number of Shares

13.96

Day High

63.06%

Free Float in %

0.2

Book Value

65.9K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	13.82	13.96	13.41	13.78	67.3K
Jul 07, 2026	13.84	14.30	13.55	13.55	107.64K
Jul 06, 2026	13.47	14.15	13.46	13.71	55.36K
Jul 02, 2026	13.88	13.88	13.05	13.35	44.95K
Jul 01, 2026	12.81	14.30	12.40	13.45	63.02K
Jun 30, 2026	11.12	14.01	11.00	13.16	296.24K
Jun 29, 2026	10.66	11.00	10.53	10.75	18.83K
Jun 26, 2026	10.41	10.66	10.38	10.53	4.56K
Jun 25, 2026	10.60	10.67	10.24	10.25	12.1K
Jun 24, 2026	10.51	10.58	10.15	10.24	22.82K
Jun 23, 2026	10.54	11.08	10.54	10.69	11.41K
Jun 22, 2026	10.85	11.00	10.60	10.68	20.38K
Jun 18, 2026	10.32	10.75	10.32	10.54	5.85K
Jun 17, 2026	10.87	10.87	10.37	10.38	12.47K
Jun 16, 2026	10.33	10.73	10.06	10.16	17.03K
Jun 15, 2026	10.51	10.54	10.00	10.05	6.77K
Jun 12, 2026	10.61	10.75	10.32	10.35	17.66K
Jun 11, 2026	10.00	10.75	10.00	10.70	6.03K
Jun 10, 2026	9.09	10.30	9.09	10.20	25.35K
Jun 09, 2026	9.77	10.05	9.48	9.74	11.34K

Contact Details

Toronto, ON M4S 3E2

Canada

https://www.promisneurosciences.com 416 847 6898

About Company

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

ProMIS Neurosciences, Inc. (NASDAQ:PMN) closed at $13.78 USD, gaining $0.23 (1.70%) from the previous close of $13.55. The stock is currently mid-range between its 52-week high and low $6.27 and $39.75. With a market capitalization of about $18.02 million, ProMIS Neurosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 35.73 thousand shares, trading with heavier-than-usual volume. Headquartered in Toronto, ON, ProMIS Neurosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Neil K. Warma, the company employs approximately 11 people and listed since January 10, 2007. ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA).

Technical Performance

PMN has shown mixed momentum, losing -0.55% over the past week and -25.37% over the past quarter, though year-to-date performance is up 19.63%. Short-term trend indicators are mixed aligned (SMA20 35.04%, SMA50 85.75%, SMA200 73.84%). The stock’s 14-day RSI is 82.14 (overbought), while the ATR of 1.63 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.52% below its high and over 232.7% above its low. Average 10-day trading volume of 93.33 thousand shares is significantly above the 3-month average of 35.83 thousand, indicating heightened recent market interest.

Valuation Metrics

ProMIS Neurosciences, Inc. trades at a P/E ratio of -0.59, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.49 suggesting the stock is closer to book value. The P/FCF stands at -0.51, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$1.26. The next quarter is forecast at -$4.66. Next year's EPS is expected at $4.67. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $4.00. The high target offers 153.99% upside. The low target suggests -70.97% downside. The mean target is $15.12. This offers 9.72% upside. ProMIS Neurosciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 12, 2026, missed forecasts by 18.87%. The prior quarter beat by 18.87%. Over the last six quarters, Apple has recorded several small beats. These include 75.0% in May 12, 2025.

Shareholding & Insider Activity

ProMIS Neurosciences, Inc. has 51.81 million shares outstanding. The public float is 29.81 million shares, elevated short interest at 1.54% of float. This equals 493.00 thousand shares. The short ratio is 0.03 days. Institutional investors hold 84.38% of the float. Insiders own 11.87%. Jeremy M. Sclar 2012 Irrevocable Family Trust holds 3.14 million shares, Sclar Jeremy M. has 3.14 million shares and ABG Management Ltd. has 700.74 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, ProMIS Neurosciences has not generated any revenue. Returns are negative, with ROA at -97.01% and ROE at -352.02%.
On valuation metrics, ProMIS Neurosciences trades at a P/E of -0.59, P/S of 0.00 and P/B of 1.49. The current ratio is 9.92 and quick ratio is 9.92.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ProMIS Neurosciences posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $14.26B (margin 0.0%). Net income was- $13.21B (EPS - $1.07).
The company ended the quarter with $12.63B in cash and short-term investments, a total debt of $0.00, and net debt of - $12.60B. Total assets were $13.62B, with equity of $3.75B. Financials further reflected weakness, with operating cash flow of - $10.84B, free cash flow of - $10.84B, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that ProMIS Neurosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.06%, with price expected at $15.58 by July 22, 2026, within a range of $14.80 to $16.45 3-Month Outlook: Projected rise of 147.9%, reaching $34.16 by October 06, 2026, with a range of $31.25 to $37.12. 1-Year Outlook: Projected loss of -4.35%, with price at $13.18 by July 08, 2027, within a range of $5.39 to $13.50.

Key Takeaways

ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares are up 19.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ProMIS Neurosciences, Inc. trading at a premium to the broader market with a P/E of -0.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.11, suggesting 2.39% upside. Our AI forecast model points to short-term strength (13.06% over two weeks), a medium-term rise (147.9% over three months), and a longer-term loss (-4.35% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ProMIS Neurosciences, Inc. (PMN) stock price?

ProMIS Neurosciences, Inc. (NASDAQ: PMN) stock price is $13.78 in the last trading session. During the trading session, PMN stock reached the peak price of $13.96 while $13.41 was the lowest point it dropped to. The percentage change in PMN stock occurred in the recent session was 1.7% while the dollar amount for the price change in PMN stock was $0.23.

PMN's industry and sector of operation?

The NASDAQ listed PMN is part of Biotechnology industry that operates in the broader Healthcare sector. ProMIS Neurosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PMN?

Dr. Ernest D. Bush Ph.D.
Head of Pharmacology/Toxicology & Senior Consultant
Mr. Dennis Chen Ph.D.
Head of Manufacturing & Senior Consultant
Dr. Larry Douglas Altstiel M.D., Ph.D.
Chief Medical Officer
Mr. Gavin T. Malenfant
Chief Operating Officer
Dr. Gail M. Farfel Ph.D.
Chief Executive Officer & Director
Dr. David Wishart Ph.D.
Chief Physics Officer
Dr. Neil R. Cashman M.D.
Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
Dr. Johanne Kaplan Ph.D.
Chief Devel. Officer
Mr. Eugene Williams
Co-Founder & Chairman

How PMN did perform over past 52-week?

PMN's closing price is 119.78% higher than its 52-week low of $6.27 where as its distance from 52-week high of $39.75 is -65.33%.

How many employees does PMN have?

Number of PMN employees currently stands at 7.

Link for PMN official website?

Official Website of PMN is: https://www.promisneurosciences.com

How do I contact PMN?

PMN could be contacted at phone 416 847 6898 and can also be accessed through its website. PMN operates from 1920 Yonge Street, Toronto, ON M4S 3E2, Canada.

How many shares of PMN are traded daily?

PMN stock volume for the day was 65.9K shares. The average number of PMN shares traded daily for last 3 months was 35.74K.

What is the market cap of PMN currently?

The market value of PMN currently stands at $18.02M with its latest stock price at $13.78 and 1.31M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	7
Beta	-0.21
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PMN Company Profile and Key Details

ProMIS Neurosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook